肝细胞生长因子基因治疗周围动脉闭塞症研究进展  

RESEARCH ADVANCE OF GENE THERAPY FOR PERIPHERAL ARTERIAL DISEASE USING HEPATOCYTE GROWTH FACTOR

作　　者：张庆林[1] 李元敏[1] 吴祖泽[1] 

机构地区：[1]军事医学科学院放射与辐射医学研究所,北京100850

出　　处：《中国修复重建外科杂志》2006年第11期1147-1150,共4页Chinese Journal of Reparative and Reconstructive Surgery

基　　金：国家高技术研究发展计划(863)资助项目(2001AA217061)

摘　　要：目的综述利用肝细胞生长因子(hepatocytegrowthfactor,HGF)基因治疗周围动脉闭塞症(peripheralarterialdisease,PAD)的实验研究和临床试验。方法查阅近年来对大鼠、家兔、犬及糖尿病大鼠缺血肢体模型或临床患者缺血部位转染HGF质粒DNA后,评价缺血肢体血流量、血管密度、血压及缺血性溃疡等相关文献。结果缺血肢体模型转染HGF质粒DNA后,缺血肢体血流量、血管密度及血压均有显著增加。肌肉注射携带HGF质粒DNA对荷瘤小鼠的肿瘤生长和转移无促进作用。/a期临床试验表明,6例患者均未观察到与基因治疗相关的不良反应,踝部绝对血压、血压指数增高,可视模拟疼痛尺度减低,缺血性溃疡长径减小、愈合或明显改善。结论携带HGF质粒DNA可能成为治疗PAD的一种新手段。Objective To introduce the studies on gene therapy for peripheral arterial disease （PAD） using plasmid DNA encoding human hepatocyte growth factor（HGF） gene. Methods Recent articles including preclinical and clinical studies were reviewed. Results Intramuscular injection of human HGF plasmid DNA into rat, rabbit, dog and diabetic hindlimb ischemic models, resulted in a significant increase in capillary density, blood flow and blood pressure. but no influence on tumor growth in mice. A clinical trial was performed in ischemic limbs of 6 critical limb ischemic patients, the result showed that no side effect caused by gene transfer was detected in all 6 patients. The pain scale and long diameter of ischemic ulcers were reduced. Conclusion Intramuscular injection of naked HGF plasmid DNA could be a safe and potential treatment for PAD.

关 键 词：肝细胞生长因子 周围动脉闭塞症 基因治疗 

分 类 号：R543[医药卫生—心血管疾病]